Ophidion CNS Carrier Technology
The blood-brain barrier (BBB) keeps out >95% of all therapeutics from the brain. This is a major impediment for drug development targeting the brain through systemically administered drugs.
Our solution, which we call the Ophidion CNS Carrier Technology (or OCCT) uses a Trojan Horse strategy to exploit endogenous receptor-mediated transport mechanisms to deliver cargo or therapeutic effectors into the brain from peripherally administered medicines (intravenous or subcutaneous route), including small molecules, gene silencing therapies, siRNA’s and other macromolecules (e.g. antibodies, oligonucleotides, etc.).
The OCCT platform can shuttle both non-covalently bound or covalently bound cargo to the brain.